Publicaciones en colaboración con investigadores/as de University Medical Center Utrecht (20)

2024

  1. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, Núm. 14

2019

  1. Local prevalence of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae intestinal carriers at admission and co-expression of ESBL and OXA-48 carbapenemase in Klebsiella pneumoniae: A prevalence survey in a Spanish University Hospital

    BMJ Open, Vol. 9, Núm. 3

2018

  1. Characterization of carbapenemase-producing Enterobacteriaceae from colonized patients in a university hospital in Madrid, Spain, during the R-GNOSIS project depicts increased clonal diversity over time with maintenance of high-risk clones

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 11, pp. 3039-3043

  2. Emergence of ESBL-producing Escherichia coli ST131-C1-M27 clade colonizing patients in Europe

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 11, pp. 2973-2980

2016

  1. The global spread of HIV-1 subtype B epidemic

    Infection, Genetics and Evolution, Vol. 46, pp. 169-179

2015

  1. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  2. Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe

    Clinical Microbiology and Infection, Vol. 21, Núm. 11, pp. 1027-1032

2014

  1. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study

    BMC Nephrology, Vol. 15, Núm. 1

  2. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2012

  1. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients

    Retrovirology, Vol. 9

2011

  1. European guidelines on the clinical management of HIV-1 tropism testing

    The Lancet Infectious Diseases, Vol. 11, Núm. 5, pp. 394-407

  2. European recommendations for the clinical use of HIV drug resistance testing: 2011 update

    AIDS Reviews, Vol. 13, Núm. 2, pp. 77-108

2009

  1. Tracing the HIV-1 subtype B mobility in Europe: A phylogeographic approach

    Retrovirology, Vol. 6

  2. Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal

    Clinical Infectious Diseases, Vol. 48, Núm. 8, pp. 1138-1151

2006

  1. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes

    Journal of Acquired Immune Deficiency Syndromes, Vol. 41, Núm. 3, pp. 352-360

2005

  1. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management

    Journal of Infectious Diseases, Vol. 192, Núm. 6, pp. 958-966

2004

  1. Updated European recommendations for the clinical use of HIV drug resistance testing

    Antiviral Therapy, Vol. 9, Núm. 6, pp. 829-848

2002

  1. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia

    Blood, Vol. 100, Núm. 12, pp. 3877-3886